208 related articles for article (PubMed ID: 21910729)
1. Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice.
Blumenfeld HJ; Tohn R; Haeryfar SM; Liu Y; Savage PB; Delovitch TL
Clin Exp Immunol; 2011 Oct; 166(1):121-33. PubMed ID: 21910729
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.
Tohn R; Blumenfeld H; Haeryfar SM; Veerapen N; Besra GS; Porcelli SA; Delovitch TL
Clin Exp Immunol; 2011 Apr; 164(1):26-41. PubMed ID: 21361909
[TBL] [Abstract][Full Text] [Related]
3. An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes.
Ly D; Tohn R; Rubin B; Blumenfeld H; Besra GS; Veerapen N; Porcelli SA; Delovitch TL
Clin Exp Immunol; 2010 May; 160(2):185-98. PubMed ID: 20015094
[TBL] [Abstract][Full Text] [Related]
4. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
[TBL] [Abstract][Full Text] [Related]
5. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
6. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets.
Naumov YN; Bahjat KS; Gausling R; Abraham R; Exley MA; Koezuka Y; Balk SB; Strominger JL; Clare-Salzer M; Wilson SB
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13838-43. PubMed ID: 11707602
[TBL] [Abstract][Full Text] [Related]
7. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes.
Chen YG; Choisy-Rossi CM; Holl TM; Chapman HD; Besra GS; Porcelli SA; Shaffer DJ; Roopenian D; Wilson SB; Serreze DV
J Immunol; 2005 Feb; 174(3):1196-204. PubMed ID: 15661873
[TBL] [Abstract][Full Text] [Related]
8. A Novel Liposome Formulation Carrying Both an Insulin Peptide and a Ligand for Invariant Natural Killer T Cells Induces Accumulation of Regulatory T Cells to Islets in Nonobese Diabetic Mice.
Akimoto H; Fukuda-Kawaguchi E; Duramad O; Ishii Y; Tanabe K
J Diabetes Res; 2019; 2019():9430473. PubMed ID: 31781669
[TBL] [Abstract][Full Text] [Related]
9. Activation of natural killer T cells by α-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis.
Yoshiga Y; Goto D; Segawa S; Horikoshi M; Hayashi T; Matsumoto I; Ito S; Taniguchi M; Sumida T
Clin Exp Immunol; 2011 May; 164(2):236-47. PubMed ID: 21391989
[TBL] [Abstract][Full Text] [Related]
10. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells.
Ly D; Mi QS; Hussain S; Delovitch TL
J Immunol; 2006 Sep; 177(6):3695-704. PubMed ID: 16951329
[TBL] [Abstract][Full Text] [Related]
11. Estrogen Therapy Delays Autoimmune Diabetes and Promotes the Protective Efficiency of Natural Killer T-Cell Activation in Female Nonobese Diabetic Mice.
Gourdy P; Bourgeois EA; Levescot A; Pham L; Riant E; Ahui ML; Damotte D; Gombert JM; Bayard F; Ohlsson C; Arnal JF; Herbelin A
Endocrinology; 2016 Jan; 157(1):258-67. PubMed ID: 26485613
[TBL] [Abstract][Full Text] [Related]
12. Activation of Invariant Natural Killer T Cell Subsets in C57BL/6J Mice by Different Injection Modes of α-galactosylceramide.
Meng M; Chen S; Gao X; Liu H; Zhao H; Zhang J; Zhang J; Chen D
Iran J Allergy Asthma Immunol; 2020 Feb; 19(1):35-44. PubMed ID: 32245319
[TBL] [Abstract][Full Text] [Related]
13. Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration.
Kuns RD; Morris ES; Macdonald KP; Markey KA; Morris HM; Raffelt NC; Banovic T; Don AL; Rowe V; Burman AC; Clouston AD; Farah C; Besra GS; Illarionov PA; Smyth MJ; Porcelli SA; Hill GR
Blood; 2009 Jun; 113(23):5999-6010. PubMed ID: 19369232
[TBL] [Abstract][Full Text] [Related]
14. NKT cells stimulated by long fatty acyl chain sulfatides significantly reduce the incidence of type 1 diabetes in nonobese diabetic mice [corrected].
Subramanian L; Blumenfeld H; Tohn R; Ly D; Aguilera C; Maricic I; Mansson JE; Buschard K; Kumar V; Delovitch TL
PLoS One; 2012; 7(5):e37771. PubMed ID: 22649557
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T-cells.
Mi QS; Ly D; Zucker P; McGarry M; Delovitch TL
Diabetes; 2004 May; 53(5):1303-10. PubMed ID: 15111500
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and functional activity of labeled CD1d glycolipid agonists.
Jervis PJ; Polzella P; Wojno J; Jukes JP; Ghadbane H; Garcia Diaz YR; Besra GS; Cerundolo V; Cox LR
Bioconjug Chem; 2013 Apr; 24(4):586-94. PubMed ID: 23458425
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
18. Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.
Courtney AN; Thapa P; Singh S; Wishahy AM; Zhou D; Sastry J
Eur J Immunol; 2011 Nov; 41(11):3312-22. PubMed ID: 21818755
[TBL] [Abstract][Full Text] [Related]
19. α-Galactosylceramide ameliorates autoimmune diabetes in non-obese diabetic mice through a suppressive effect mediated by CD8+ T cells.
Chuang YP; Lin YC; Sytwu HK
Immunol Lett; 2011 Jul; 138(1):54-62. PubMed ID: 21392534
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional characterization of a novel nonglycosidic type I NKT agonist with immunomodulatory properties.
Kerzerho J; Yu ED; Barra CM; Alari-Pahissa E; Girardi E; Harrak Y; Lauzurica P; Llebaria A; Zajonc DM; Akbari O; Castaño AR
J Immunol; 2012 Mar; 188(5):2254-65. PubMed ID: 22301545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
